老年黑色素瘤患者免疫检查点抑制剂治疗后的免疫相关不良事件
该研究为基于Medicare理赔数据与SEER癌症登记数据库链接的人群队列研究,纳入2011年1月1日至2015年12月31日诊断的4489例白人(66.9%为男性,中位年龄74.9岁)首次原发皮肤黑色素瘤(II-IV期或未知期)老年患者,随访至2015年12月31日。中位随访1.4年期间,35.1%的患者(1576例)理赔记录出现免疫相关AE。使用ICI(418例)与自身免疫相关AE(HR 2.5;95% CI 1.6-4.0)及其他免疫相关AE(HR 2.2;95% CI 1.7-2.8)相关,多数关联在首次ICI理赔后6个月内更明显,且无论基线有无自身免疫病史均相似。首次ICI理赔后6个月累积发生率:自身免疫相关AE为13.7%(95% CI 9.7%-18.3%),其他免疫相关AE为46.8%(95% CI 40.7%-52.7%)。作者认为部分发现与ICI临床试验一致,另一些需进一步研究。
要点
- 老年皮肤黑色素瘤患者使用ICI与自身免疫相关AE相关(HR 2.5;95% CI 1.6-4.0),包括原发性肾上腺皮质功能不全(HR 9.9;95% CI 4.5-21.5)和溃疡性结肠炎(HR 8.6;95% CI 2.8-26.3)。
- ICI与其他免疫相关AE相关(HR 2.2;95% CI 1.7-2.8),包括库欣综合征(HR 11.8;95% CI 1.4-97.2)、甲状腺功能亢进(HR 6.3;95% CI 2.0-19.5)、甲状腺功能减退(HR 3.8;95% CI 2.4-6.1)、垂体功能减退(HR 19.8;95% CI 5.4-72.9)、其他垂体腺疾病(HR 6.0;
- 多数关联在首次ICI理赔后6个月内更明显,且无论基线有无自身免疫病史均相似。
- 首次ICI理赔后6个月累积发生率:自身免疫相关AE为13.7%(95% CI 9.7%-18.3%),其他免疫相关AE为46.8%(95% CI 40.7%-52.7%)。
- 中位随访1.4年期间,35.1%的患者(1576/4489)理赔记录出现免疫相关AE。
适用人群与场景
- 白人、2011-2015年经SEER报告诊断为II-IV期或未知期(AJCC第6版)首次原发皮肤黑色素瘤、年龄66.0-84.9岁(中位74.9岁)的老年患者,随访至2015年12月31日。
研究设计与关键结果
- 研究类型:基于Medicare理赔数据与SEER癌症登记数据库链接的人群队列研究,纳入4489例白人首次原发皮肤黑色素瘤患者(3002例男性[66.9%];中位年龄74.9岁,范围66.0-84.9岁),随访中位1.4年(范围0-5.0年)。
- 暴露:用于治疗黑色素瘤的免疫检查点抑制剂(418例报告使用)。
- 主要结局:ICI使用与自身免疫相关AE相关(HR 2.5;95% CI 1.6-4.0),包括原发性肾上腺皮质功能不全(HR 9.9;95% CI 4.5-21.5)和溃疡性结肠炎(HR 8.6;95% CI 2.8-26.3)。
- ICI与其他免疫相关AE相关(HR 2.2;95% CI 1.7-2.8),包括库欣综合征(HR 11.8;95% CI 1.4-97.2)、甲状腺功能亢进(HR 6.3;95% CI 2.0-19.5)、甲状腺功能减退(HR 3.8;95% CI 2.4-6.1)、垂体功能减退(HR 19.8;95% CI 5.4-72.9)、其他垂体腺疾病(HR 6.0;95% CI 1.2-30.2)、腹泻(HR 3.5;95% CI 2.5-4.9)及脓毒症或败血症(HR 2.2;95% CI 1.4-3.3)。
- 随访期间1576例(35.1%)理赔记录出现免疫相关AE。
- 多数关联在首次ICI理赔后6个月内更明显,且无论基线有无自身免疫病史均相似。
- 首次ICI理赔后6个月累积发生率:自身免疫相关AE为13.7%(95% CI 9.7%-18.3%),其他免疫相关AE为46.8%(95% CI 40.7%-52.7%)。
证据类型、等级与局限
- 证据类型:基于Medicare理赔数据与SEER登记链接的人群队列研究。
- 局限:部分发现与ICI临床试验一致,另一些需进一步研究(原文:others warrant further investigation)。
对床旁实践的改变
- 作者认为:随着ICI使用持续快速扩大,持续研究免疫相关AE谱可能优化患者疾病管理。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Immune checkpoint inhibitors (ICIs) have improved survival in patients with advanced melanoma but can be associated with a spectrum of immune-related adverse events (AEs), including both autoimmune-related AEs and other immune-related inflammatory AEs. These associations have primarily been evaluated in clinical trials that include highly selected patients, with older adults often underrepresented.
OBJECTIVE: To evaluate the association between use of ICIs and immune-related AEs (autoimmune and other immune related) among older patients with cutaneous melanoma.
DESIGN, SETTING, AND PARTICIPANTS: A population-based cohort study was conducted from January 1, 2011, to December 31, 2015. Data were analyzed from January 31 to May 31, 2021. With use of a linked database of Medicare claims and Surveillance, Epidemiology, and End Results (SEER) Program population-based cancer registries, patients of White race diagnosed with stages II-IV or unknown (American Joint Committee on Cancer, AJCC Cancer Staging Manual 6th edition) first primary cutaneous melanoma during 2011-2015, as reported to SEER, and followed up through December 31, 2015, were identified.
EXPOSURES: Immune checkpoint inhibitors for treatment of melanoma.
MAIN OUTCOMES AND MEASURES: The association between ICIs and immune-related AEs ascertained from Medicare claims data was estimated using multivariable Cox regression with hazard ratios (HRs) and 95% CIs and with cumulative incidence accounting for competing risk of death.
RESULTS: The study included 4489 patients of White race with first primary melanoma (3002 men [66.9%]; median age, 74.9 [range, 66.0-84.9] years). During follow-up (median, 1.4 [range, 0-5.0] years), 1576 patients (35.1%) had an immune-related AE on a Medicare claim. Use of ICIs (reported for 418 patients) was associated with autoimmune-related AEs (HR, 2.5; 95% CI, 1.6-4.0), including primary adrenal insufficiency (HR, 9.9; 95% CI, 4.5-21.5) and ulcerative colitis (HR, 8.6; 95% CI, 2.8-26.3). Immune checkpoint inhibitors also were associated with other immune-related AEs (HR, 2.2; 95% CI, 1.7-2.8), including Cushing syndrome (HR, 11.8; 95% CI, 1.4-97.2), hyperthyroidism (HR, 6.3; 95% CI, 2.0-19.5), hypothyroidism (HR, 3.8; 95% CI, 2.4-6.1), hypopituitarism (HR, 19.8; 95% CI, 5.4-72.9), other pituitary gland disorders (HR, 6.0; 95% CI, 1.2-30.2), diarrhea (HR, 3.5; 95% CI, 2.5-4.9), and sepsis or septicemia (HR, 2.2; 95% CI, 1.4-3.3). Most associations were pronounced within 6 months following the first ICI claim and comparable with or without a baseline history of autoimmune disease. The cumulative incidence at 6 months following the first ICI claim was 13.7% (95% CI, 9.7%-18.3%) for autoimmune-related AEs and 46.8% (95% CI, 40.7%-52.7%) for other immune-related AEs.
CONCLUSIONS AND RELEVANCE: In this cohort study of older adults with melanoma, ICIs were associated with autoimmune-related AEs and other immune-related AEs. Although some findings were consistent with clinical trials of ICIs, others warrant further investigation. As ICI use continues to expand rapidly, ongoing investigation of the spectrum of immune-related AEs may optimize management of disease in patients.
参考来源
- Schonfeld SJ, Tucker MA, Engels EA, et al. Immune-Related Adverse Events After Immune Checkpoint Inhibitors for Melanoma Among Older Adults. JAMA Netw Open. 2022. PMID: 35315916. doi:10.1001/jamanetworkopen.2022.3461
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。